Details

Autor(en) / Beteiligte

• Gygi, Jeremy P
• Maguire, Cole
• Patel, Ravi K
• Shinde, Pramod
• Konstorum, Anna
• Shannon, Casey P
• Xu, Leqi
• Hoch, Annmarie
• Jayavelu, Naresh Doni
• Haddad, Elias K
• Reed, Elaine F
• Kraft, Monica
• McComsey, Grace A
• Metcalf, Jordan P
• Ozonoff, Al
• Esserman, Denise
• Cairns, Charles B
• Rouphael, Nadine
• Bosinger, Steven E
• Kim-Schulze, Seunghee
• Krammer, Florian
• Rosen, Lindsey B
• van Bakel, Harm
• Wilson, Michael
• Eckalbar, Walter L
• Maecker, Holden T
• Langelier, Charles R
• Steen, Hanno
• Altman, Matthew C
• Montgomery, Ruth R
• Levy, Ofer
• Melamed, Esther
• Pulendran, Bali
• Diray-Arce, Joann
• Smolen, Kinga K
• Fragiadakis, Gabriela K
• Becker, Patrice M
• Sekaly, Rafick P
• Ehrlich, Lauren Ir
• Fourati, Slim
• Peters, Bjoern
• Kleinstein, Steven H
• Guan, Leying

Titel

Integrated longitudinal multiomics study identifies immune programs associated with acute COVID-19 severity and mortality

Ist Teil von

• The Journal of clinical investigation, 2024-05, Vol.134 (9), p.1-17

Ort / Verlag

United States: American Society for Clinical Investigation

Erscheinungsjahr

2024

Link zum Volltext

Quelle

MEDLINE

Beschreibungen/Notizen

• BACKGROUNDPatients hospitalized for COVID-19 exhibit diverse clinical outcomes, with outcomes for some individuals diverging over time even though their initial disease severity appears similar to that of other patients. A systematic evaluation of molecular and cellular profiles over the full disease course can link immune programs and their coordination with progression heterogeneity.METHODSWe performed deep immunophenotyping and conducted longitudinal multiomics modeling, integrating 10 assays for 1,152 Immunophenotyping Assessment in a COVID-19 Cohort (IMPACC) study participants and identifying several immune cascades that were significant drivers of differential clinical outcomes.RESULTSIncreasing disease severity was driven by a temporal pattern that began with the early upregulation of immunosuppressive metabolites and then elevated levels of inflammatory cytokines, signatures of coagulation, formation of neutrophil extracellular traps, and T cell functional dysregulation. A second immune cascade, predictive of 28-day mortality among critically ill patients, was characterized by reduced total plasma Igs and B cells and dysregulated IFN responsiveness. We demonstrated that the balance disruption between IFN-stimulated genes and IFN inhibitors is a crucial biomarker of COVID-19 mortality, potentially contributing to failure of viral clearance in patients with fatal illness.CONCLUSIONOur longitudinal multiomics profiling study revealed temporal coordination across diverse omics that potentially explain the disease progression, providing insights that can inform the targeted development of therapies for patients hospitalized with COVID-19, especially those who are critically ill.TRIAL REGISTRATIONClinicalTrials.gov NCT04378777.FUNDINGNIH (5R01AI135803-03, 5U19AI118608-04, 5U19AI128910-04, 4U19AI090023-11, 4U19AI118610-06, R01AI145835-01A1S1, 5U19AI062629-17, 5U19AI057229-17, 5U19AI125357-05, 5U19AI128913-03, 3U19AI077439-13, 5U54AI142766-03, 5R01AI104870-07, 3U19AI089992-09, 3U19AI128913-03, and 5T32DA018926-18); NIAID, NIH (3U19AI1289130, U19AI128913-04S1, and R01AI122220); and National Science Foundation (DMS2310836).